While details of the guidance remain closely held, some clues are likely found in the FDA’s late Friday letter approving Novavax’s Covid vaccine. Who can get it: The license covers a limited population — adults 65 and older and people ages 12 to 64 with at least one underlying condition putting them at high risk for severe disease — compared with the two messenger RNA shots available for Covid recommended for all people 12 and older.